Here Thursday’s Wall Street: Analysts Push Key Stocks
U.S. equities moved higher on Thursday as a wave of fresh Wall Street analyst calls buoyed major names across healthc...
When To Choose Stock Picking Over Index Funds
Stock picking may pay off in certain market conditions and for investors with time and expertise. Learn factors to consider before deviating from index funds.
26,454 articlesMicron 268% This Year Sparks Caution on Pullback Risks
Micron Technology has powered higher this year on AI demand, delivering a staggering rally. Yet veteran traders urge ...
HeartBeam (Beat) 2025 Earnings: What Investors Need
HeartBeam heads into 2025 earnings with a mix of potential breakthroughs and headwinds. This guide explains what the ...
Buy, Sell, Hold Broadcom Ahead of Key Earnings Tomorrow
Broadcom prepares to report earnings, with AI-powered momentum fueling expectations. Investors confront the question ...
Better After Chip Sell-Off: Nvidia or AMD Buyers Guide
When chip stocks swing, choosing the right side matters. This guide weighs Nvidia vs AMD after the sell-off, with num...
Does This Stock Have the Most Impregnable Defenses?
Intercontinental Exchange sits at the heart of global markets, combining exchanges, data, and clearing. This piece ex...
From Crisis 459% Gain: Intel's Bold Turnaround Now
Intel overcame a tough 12 months to deliver a striking rebound. Analysts say the AI-led strategy and foundry expansio...
Cerebras' First Earnings Report: AI Takeaway for Investors
Cerebras' first earnings report brings a clear message for AI stock shoppers: growth alone isn't enough. Here's how t...
Nebius's Stock Surges Latest After Meta Deal, NVIDIA Tie-Up
Nebius’s stock surges latest after the company lands a Meta partnership valued at up to $27 billion, building on a re...
Lululemon Athletica After Latest Earnings: Buy or Not
Lululemon faces a pivotal moment after its latest earnings. This analysis breaks down what's working, what's slowing,...
Netflix Nearing 52-Week Low: What Investors Should Do
Netflix trades near its 52-week low as operating strength clashes with subscriber-growth concerns. A stronger FY26 ca...
Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Popular Topics
Fable
Smart Money Moves For Everyday Life
Investment Strategies In Energy Sector
Best Index Funds For Retirement
Investment Strategies
Untitled D6eff7ea
Crypto For Beginners
Best Dividend Etfs
Index
Innovative Skincare Clinical
Dutch Salary
Blue Owl
Budget
Ai Healthcare News
Penalty Vs No Penalty Depending On Lock Status